HK1247789A1 - 用於治療水腫的組合物和方法 - Google Patents
用於治療水腫的組合物和方法Info
- Publication number
- HK1247789A1 HK1247789A1 HK18107279.7A HK18107279A HK1247789A1 HK 1247789 A1 HK1247789 A1 HK 1247789A1 HK 18107279 A HK18107279 A HK 18107279A HK 1247789 A1 HK1247789 A1 HK 1247789A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- edema
- compositions
- treatment
- methods
- Prior art date
Links
- 206010030113 Oedema Diseases 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/275—Nitriles; Isonitriles
- A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/401—Proline; Derivatives thereof, e.g. captopril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
- A61K38/13—Cyclosporins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Dermatology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562112273P | 2015-02-05 | 2015-02-05 | |
PCT/US2016/016680 WO2016127013A1 (en) | 2015-02-05 | 2016-02-05 | Compositions and methods for treatment of edema |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1247789A1 true HK1247789A1 (zh) | 2018-10-05 |
Family
ID=56564721
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK18107279.7A HK1247789A1 (zh) | 2015-02-05 | 2018-06-04 | 用於治療水腫的組合物和方法 |
Country Status (8)
Country | Link |
---|---|
US (4) | US10251871B2 (zh) |
EP (1) | EP3253211A4 (zh) |
JP (2) | JP6704403B2 (zh) |
CN (2) | CN114588154A (zh) |
AU (2) | AU2016215173B2 (zh) |
CA (1) | CA2975879A1 (zh) |
HK (1) | HK1247789A1 (zh) |
WO (1) | WO2016127013A1 (zh) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10251871B2 (en) * | 2015-02-05 | 2019-04-09 | Memorial Sloan Kettering Cancer Center | Compositions and methods for treatment of edema |
EP3500308A4 (en) * | 2016-08-18 | 2020-04-22 | Memorial Sloan Kettering Cancer Center | INHIBITION OF THE SPHINGOSIN-1-PHOSPHATE RECEPTOR FOR TREATING AND PREVENTING LYMPHEDEMES |
EP4427815A3 (en) * | 2018-09-14 | 2024-11-06 | Puretech Lyt 100, Inc. | Deuterium-enriched pirfenidone and methods of use thereof |
US20220040138A1 (en) * | 2018-11-05 | 2022-02-10 | Apramitha Innovations Private Limited | Teriflunomide topical pharmaceutical compositions |
WO2021186401A1 (en) * | 2020-03-18 | 2021-09-23 | Puretech Lyt 100, Inc. | Methods of treating lymphedema with deupirfenidone |
CN112642065B (zh) * | 2020-12-28 | 2022-08-02 | 锐可医疗科技(上海)有限公司 | 激光治疗仪及存储介质 |
WO2024059336A1 (en) * | 2022-09-18 | 2024-03-21 | Memorial Sloan Kettering Cancer Center | Inhibition of protease-activated receptor 2 (par2) pathway for treatment and prevention of lymphedema |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005011669A1 (ja) * | 2003-08-05 | 2005-02-10 | Dainippon Sumitomo Pharma Co., Ltd. | 経皮投与用医薬組成物 |
US20050158371A1 (en) * | 2002-02-12 | 2005-07-21 | Sumitomo Pharmaceuticals Co., Ltd. | Novel external agent |
US7232828B2 (en) * | 2002-08-10 | 2007-06-19 | Bethesda Pharmaceuticals, Inc. | PPAR Ligands that do not cause fluid retention, edema or congestive heart failure |
CN101460060A (zh) * | 2006-03-01 | 2009-06-17 | 特莱斯特拉塔公司 | 局部治疗焦油响应性皮肤病用的组合物和方法 |
BRPI0709016A2 (pt) * | 2006-03-23 | 2011-06-21 | Macusight Inc | formulações e métodos para doenças ou condições relacionadas com a permeabilidade vascular |
CN101484167B (zh) * | 2006-06-15 | 2012-07-04 | 上海睿星基因技术有限公司 | 吡啶酮类衍生物预防和治疗放射性肺损伤的用途 |
WO2008116135A2 (en) * | 2007-03-22 | 2008-09-25 | Cytotech Labs, Llc | Topical formulations having enhanced bioavailability |
CA2741954A1 (en) * | 2008-10-29 | 2010-05-06 | Pacific Therapeutics Ltd. | Composition and method for treating fibrosis |
US7635707B1 (en) | 2008-11-10 | 2009-12-22 | Intermune, Inc. | Pirfenidone treatment for patients with atypical liver function |
TW201032796A (en) * | 2009-02-04 | 2010-09-16 | Bipar Sciences Inc | Treatment of lung cancer with a PARP inhibitor in combination with a growth factor inhibitor |
DE102010015143A1 (de) * | 2010-04-16 | 2011-10-20 | Cts Chemical Industries Ltd. | Stabile flüssige ölige gebrauchsfertige Formulierungen, Herstellung davon und Verwendung davon |
US10251871B2 (en) * | 2015-02-05 | 2019-04-09 | Memorial Sloan Kettering Cancer Center | Compositions and methods for treatment of edema |
US10292961B2 (en) * | 2015-07-15 | 2019-05-21 | Hangzhou Dac Biotech Co., Ltd. | Disulfur bridge linkers for conjugation of a cell-binding molecule |
-
2016
- 2016-02-05 US US15/549,156 patent/US10251871B2/en active Active
- 2016-02-05 CA CA2975879A patent/CA2975879A1/en active Pending
- 2016-02-05 AU AU2016215173A patent/AU2016215173B2/en active Active
- 2016-02-05 EP EP16747309.9A patent/EP3253211A4/en active Pending
- 2016-02-05 CN CN202210078205.6A patent/CN114588154A/zh active Pending
- 2016-02-05 CN CN201680016894.0A patent/CN107427007B/zh not_active Expired - Fee Related
- 2016-02-05 WO PCT/US2016/016680 patent/WO2016127013A1/en active Application Filing
- 2016-02-05 JP JP2017541301A patent/JP6704403B2/ja not_active Expired - Fee Related
-
2018
- 2018-06-04 HK HK18107279.7A patent/HK1247789A1/zh unknown
-
2019
- 2019-02-15 US US16/277,942 patent/US10874651B2/en active Active
-
2020
- 2020-02-18 AU AU2020201161A patent/AU2020201161B2/en active Active
- 2020-03-12 JP JP2020042965A patent/JP6926263B2/ja active Active
- 2020-11-17 US US16/950,652 patent/US11583523B2/en active Active
-
2023
- 2023-01-27 US US18/102,437 patent/US12144805B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
US12144805B2 (en) | 2024-11-19 |
EP3253211A1 (en) | 2017-12-13 |
CN107427007B (zh) | 2022-02-11 |
US20200016137A1 (en) | 2020-01-16 |
US20210069164A1 (en) | 2021-03-11 |
US10874651B2 (en) | 2020-12-29 |
AU2016215173A1 (en) | 2017-08-24 |
JP2020114830A (ja) | 2020-07-30 |
JP6926263B2 (ja) | 2021-08-25 |
EP3253211A4 (en) | 2018-10-31 |
AU2016215173B2 (en) | 2019-11-21 |
CN107427007A (zh) | 2017-12-01 |
US20230241043A1 (en) | 2023-08-03 |
US10251871B2 (en) | 2019-04-09 |
AU2020201161B2 (en) | 2021-07-15 |
JP6704403B2 (ja) | 2020-06-03 |
CA2975879A1 (en) | 2016-08-11 |
WO2016127013A1 (en) | 2016-08-11 |
AU2020201161A1 (en) | 2020-03-05 |
JP2018504436A (ja) | 2018-02-15 |
US11583523B2 (en) | 2023-02-21 |
CN114588154A (zh) | 2022-06-07 |
US20180028514A1 (en) | 2018-02-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL258955A (en) | Preparations and methods for the treatment of cancer | |
IL253803B (en) | A preparation for the treatment of hypothyroidism | |
IL247942A0 (en) | Compositions and methods for drops in macular edema as a result of diabetes | |
HK1247789A1 (zh) | 用於治療水腫的組合物和方法 | |
RS61703B1 (sr) | Kompozicije i postupci za lečenje i prevenciju zapaljenja | |
HK1244711A1 (zh) | Hmgb1介導的炎症的治療 | |
SG11201702554QA (en) | Compositions and methods for the treatment of multiple sclerosis | |
HK1255221A1 (zh) | 使用卡多曲組合物進行治療的方法 | |
HK1258502A1 (zh) | 用於治療高胱氨酸尿症的組合物和方法 | |
IL259710A (en) | Preparations and methods for the treatment of Davidson's disease (microvillus inclusion disease) and related diseases | |
HK1250145A1 (zh) | 治療多發性骨髓瘤的組合物和方法 | |
HK1255695A1 (zh) | 用於治療眼瞼下垂的組合物和方法 | |
GB201511799D0 (en) | Composition and methods of treatment | |
HK1243937A1 (zh) | 治療疾病的方法 | |
GB201621737D0 (en) | Compositions and methods of treatment | |
IL257407A (en) | Compositions and methods for treating wounds | |
IL252707B (en) | Compositions and methods for treating diseases | |
DK3313207T3 (en) | Compositions and methods for the treatment of malnutrition | |
GB201605127D0 (en) | Composition and methods of treatment | |
HK1252385A1 (zh) | 錫生藤提取物治療登革熱的用途 | |
HK1243343A1 (zh) | 含脫輔基水母發光蛋白的組合物及其用於治療神經元炎症的方法 | |
GB201512139D0 (en) | Methods of treatment | |
SG10201913141UA (en) | Treatment of alphavirus-induced inflammation | |
GB201521083D0 (en) | Compositions for treatment and methods thereof | |
AU2015903210A0 (en) | Compositions and methods of treatment |